Pall, Cobra and CGTC collaborate on continuous method for gene therapies

By Flora Southey

- Last updated on GMT

(Image: Getty/Dr_Microbe)
(Image: Getty/Dr_Microbe)

Related tags Gene therapy adeno-associated virus Uk

Innovate UK has awarded £1.5m to three co-winners to investigate continuous manufacturing for AAV production.

Contract development and manufacturing organisation (CDMO) Cobra Biologics, bioprocessing vendor Pall Biotech, and independent research and technology organisation, the Cell and Gene Therapy Catapult (CGTC), were granted a share of £1.5m ($1.9m).

Instigated by government organisation, Innovate UK, the funding will be used to investigate continuous manufacturing methodology for “more efficient production” ​of adeno-associated virus’ (AAV) – designed to infect cells with gene therapies.

According to Pall Biotech VP, Mario Philips, yields for downstream processing of AAVs are currently low, and the production process is “costly in both time and consumables”.

“With this project, we hope to advance the AAV purification process and affect a 25% or more step change in purification yields,” ​he added.

CGTC CEO, Keith Thompson, similarly predicts the collaboration to “take a major step” ​towards a more efficient, continuous process for gene therapy production.

“As we move forward, we will create a scalable continuous process that increases efficiencies in time and cost, to make commercialisation of gene therapies safer, faster, and cheaper than ever before,” ​he added in a statement.

The announcement comes days after the UK government granted £4.3m​ to Oxford BioMedica, Autulus, and Arc Trinova, to adopt digital technologies in their manufacturing processes.

The government also announced a separate investment of £3m in the UK’s Advanced Therapy Treatment Centres, to support the delivery of cell and gene therapies.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars